Intellia Therapeutics Inc (NTLA) FinancialsNTLAIntellia Therapeutics Inc

Evaluating the bottom line, Intellia Therapeutics, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1472.25%, while the net margin is -1392.27%. These profitability ratios, combined with a Return on Equity (ROE) of -55.44%, provide a clear picture of how effectively NTLA converts its operational activities into shareholder value.

In the context of the broader market, NTLA competes directly with industry leaders such as ZBIO and NUVB. With a market capitalization of $1.60B, it holds a significant position in the sector. When comparing efficiency, NTLA's gross margin of 100.00% stands against ZBIO's 100.00% and NUVB's 86.54%. Such benchmarking helps identify whether Intellia Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Intellia has reported continuous losses, with a net income of -$106,634,000 in Q2 2026 and an EPS of -0.80, reflecting ongoing financial struggles. The gross margin remains high at 100%, but this does not compensate for the substantial net losses.